一名患有胸腺鳞状细胞癌并伴有多处肺转移的患者对抗程序性死亡蛋白1（anti-PD-1）治疗产生显著反应。
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
作者信息
Yang Yan, Ding Liren, Wang Pingli
机构信息
Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
出版信息
J Thorac Dis. 2016 Jul;8(7):E535-7. doi: 10.21037/jtd.2016.06.32.
Abstract
Immunotherapy directed at the programmed cell death-1 receptor (PD-1) or its ligand PD-L1 has demonstrated efficacy in some malignancies, such as metastatic melanoma and non-small-cell lung cancer (NSCLC). Compared with cytotoxic chemotherapy, radiotherapy or molecular targeted agent, it is an innovative way to treat malignancies with durable clinical responses and manageable adverse. We present a case of female patient with squamous cell carcinoma of thymus involving multiple lung metastases, who was successfully treated with anti-PD-1 monoclonal antibody, pembrolizumab.
摘要
针对程序性细胞死亡蛋白1受体（PD-1）或其配体PD-L1的免疫疗法已在某些恶性肿瘤中显示出疗效，如转移性黑色素瘤和非小细胞肺癌（NSCLC）。与细胞毒性化疗、放疗或分子靶向药物相比，它是一种治疗恶性肿瘤的创新方法，具有持久的临床反应和可控的不良反应。我们报告一例患有胸腺鳞状细胞癌并伴有多发肺转移的女性患者，该患者通过抗PD-1单克隆抗体帕博利珠单抗成功治愈。
相似文献
1
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.一名患有胸腺鳞状细胞癌并伴有多处肺转移的患者对抗程序性死亡蛋白1（anti-PD-1）治疗产生显著反应。
J Thorac Dis. 2016 Jul;8(7):E535-7. doi: 10.21037/jtd.2016.06.32.
2
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.帕博利珠单抗治疗一名接受过大量治疗的胸腺鳞状细胞癌合并心脏损害患者：病例报告及文献综述
Front Oncol. 2020 Aug 18;10:1478. doi: 10.3389/fonc.2020.01478. eCollection 2020.
3
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
4
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.晚期肺癌的联合化疗和程序性死亡受体 1/程序性死亡配体 1 抑制剂治疗的毒性管理。
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
5
Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies.转移性鳞状细胞非小细胞肺癌（NSCLC）：免疫疗法打破药物治疗模式
Drugs Context. 2015 Oct 14;4:212289. doi: 10.7573/dic.212289. eCollection 2015.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗肿瘤表达程序性死亡配体1的转移性非小细胞肺癌患者。
Oncologist. 2016 May;21(5):643-50. doi: 10.1634/theoncologist.2015-0498. Epub 2016 Mar 29.
8
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
9
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
10
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.帕博利珠单抗作为程序性死亡受体配体1（PD-L1）阳性晚期非小细胞肺癌患者的一线治疗：一项1期试验。
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
引用本文的文献
1
Current immunotherapy for thymic epithelial tumors: a narrative review.胸腺上皮肿瘤的当前免疫治疗：一篇叙述性综述。
Mediastinum. 2024 Oct 11;8:47. doi: 10.21037/med-24-24. eCollection 2024.
2
Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.免疫疗法和靶向疗法在胸腺上皮肿瘤中的疗效：一项系统评价。
Biomedicines. 2023 Oct 8;11(10):2722. doi: 10.3390/biomedicines11102722.
3
Current Treatment Approaches for Thymic Epithelial Tumors.胸腺上皮肿瘤的当前治疗方法
Life (Basel). 2023 May 12;13(5):1170. doi: 10.3390/life13051170.
4
Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors.权衡晚期胸腺上皮肿瘤中不良事件风险与免疫治疗疗效
Cancers (Basel). 2022 Dec 31;15(1):289. doi: 10.3390/cancers15010289.
5
A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis.一项对71例胸腺癌患者的单中心分析：手术方式及预后的时间变化
J Thorac Dis. 2022 Sep;14(9):3211-3220. doi: 10.21037/jtd-22-490.
6
Unraveling the Immune Microenvironment of Thymic Epithelial Tumors: Implications for Autoimmunity and Treatment.解析胸腺瘤的免疫微环境：自身免疫与治疗的关联。
Int J Mol Sci. 2022 Jul 16;23(14):7864. doi: 10.3390/ijms23147864.
7
Molecular predictors of response to pembrolizumab in thymic carcinoma.胸腺癌帕博利珠单抗治疗反应的分子预测因子。
Cell Rep Med. 2021 Sep 3;2(9):100392. doi: 10.1016/j.xcrm.2021.100392. eCollection 2021 Sep 21.
8
The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.免疫疗法在胸腺上皮肿瘤中的疗效与安全性：效果更佳，风险更高：一项系统综述
J Thorac Dis. 2021 Aug;13(8):5093-5103. doi: 10.21037/jtd-21-290.
9
A CRISPR View of Biological Mechanisms.生物机制的CRISPR视角
Discoveries (Craiova). 2016 Dec 31;4(4):e69. doi: 10.15190/d.2016.16.
10
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.胸腺上皮性肿瘤中的程序性死亡配体 1（PD-L1）表达与肿瘤浸润淋巴细胞
J Clin Med. 2019 Nov 1;8(11):1833. doi: 10.3390/jcm8111833.
本文引用的文献
1
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.前列腺癌、肾癌和尿路上皮癌中免疫检查点阻断：概述
Urol Oncol. 2016 Apr;34(4):171-81. doi: 10.1016/j.urolonc.2016.01.006. Epub 2016 Feb 28.
2
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.帕博利珠单抗和纳武利尤单抗：用于晚期黑色素瘤的PD-1抑制剂。
Am J Health Syst Pharm. 2016 Feb 15;73(4):193-201. doi: 10.2146/ajhp140768.
3
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.非小细胞肺癌中PD-1和PD-L1的表达表明在特定亚组中预后良好。
PLoS One. 2015 Aug 27;10(8):e0136023. doi: 10.1371/journal.pone.0136023. eCollection 2015.
4
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.根据程序性死亡配体-1（PD-L1）的肿瘤表达情况，纳武单抗、派姆单抗和MPDL3280A的差异活性：黑色素瘤、肺癌和泌尿生殖系统癌症试验的敏感性分析
PLoS One. 2015 Jun 18;10(6):e0130142. doi: 10.1371/journal.pone.0130142. eCollection 2015.
5
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
6
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
7
Toxicity of checkpoint inhibitors.
Chin Clin Oncol. 2014 Sep;3(3):31. doi: 10.3978/j.issn.2304-3865.2014.08.03.
8
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.胸腺瘤和胸腺癌中PD-L1的免疫组化状态。
Lung Cancer. 2015 May;88(2):154-9. doi: 10.1016/j.lungcan.2015.03.003. Epub 2015 Mar 10.
9
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.纳武单抗（一种抗程序性死亡蛋白1免疫检查点抑制剂）用于晚期难治性鳞状非小细胞肺癌患者的活性和安全性（CheckMate 063）：一项2期单臂试验
Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.
Zotero 插件